Natamycin

Summary

Natamycin (CHEMBL1200656) is an approved small-molecule ophthalmology drug (ATC S01AA10); indicated across 4 conditions including eye infectious disorder and acanthamoeba keratitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AA10 (+4 more)
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 665.7 Da · C33H47NO13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200656
Name	Natamycin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5284447
ChEBI	CHEBI:7488
ATC	S01AA10, D01AA02, A07AA03, A01AB10, G01AA02
Molecular formula	C33H47NO13
Molecular weight	665.7
InChIKey	NCXMLFZGDNKEPB-FFPOYIOWSA-N

SMILES: C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O

IUPAC name: (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

ChEBI definition: A macrolide antibiotic that has formula C33H47NO13, produced by several Streptomyces species including Streptomyces natalensis. It exhibits broad spectrum antifungal activity and used in eye drops, and as a food preservative, and also as a postharvest biofungicide for citrus and other fruit crops.

Pharmacological roles (ChEBI): apoptosis inducer, ophthalmology drug, antifungal agrochemical.

Other ChEBI roles (chemical / environmental): antimicrobial food preservative, bacterial metabolite.

Also known as: ANTIBIOTIC A-5283, CL 12,625, CL-12625, Delvocid, E-235, E235, INS NO.235, INS-235, Mycophyt, Myprozine, Natacyn, Natamicina

Patent coverage: 10,312 distinct patent families (34,313 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye infectious disorder	4	MONDO:0043885	EFO:1001888
Acanthamoeba keratitis	3	MONDO:0005629	EFO:0007126
fungal infectious disease	2	MONDO:0002041	MONDO:0002041

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00996736	PHASE3	COMPLETED	Mycotic Ulcer Treatment Trial I
NCT02731638	PHASE3	COMPLETED	Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
NCT05110001	PHASE3	COMPLETED	Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
NCT00557362	PHASE1/PHASE2	COMPLETED	Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
NCT05655689	Not specified	COMPLETED	The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).